Visium Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Visium Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-832	Closed	-$424K	–	1140
2015 Q2	$424K	Sell	832 -7,594	-90%	-$3.71M	0.01%	698
2015 Q1	$3.8M	Sell	8,426 -162,339	-95%	-$68.8M	0.06%	311
2014 Q4	$70.1M	Buy	170,765 +54,677	+47%	+$21.5M	0.99%	16
2014 Q3	$41.9M	Sell	116,088 -63,640	-35%	-$21.3M	0.62%	24
2014 Q2	$50.8M	Sell	179,728 -106,835	-37%	-$31.7M	0.79%	14
2014 Q1	$86M	Buy	+286,563	New	+$88.3M	1.39%	10
2013 Q4	–	Sell	-680	Closed	-$213K	–	961
2013 Q3	$213K	Sell	680 -82,249	-99%	-$21.6M	﹤0.01%	699
2013 Q2	$18.6M	Buy	+82,929	New	+$19.3M	0.44%	49

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Visium Asset Management's REGN Position: Q3 2015 in Review

Visium Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2015, closing a stake of 832 shares — an estimated $424K sold.

Visium Asset Management first reported a position in REGN in Q2 2013 and held it in 8 quarters. The position peaked at $86M in Q1 2014. 561 funds tracked by Wall St. Rank hold REGN as of Q3 2015.

Visium Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Visium Asset Management sold 832 Regeneron Pharmaceuticals shares in Q3 2015, an estimated $424K.
Visium Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Visium Asset Management's Regeneron Pharmaceuticals position peaked at $86M in Q1 2014.
561 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2015.

Based on Visium Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.